What Are the Long-term Outcomes of Mortality, Quality of Life, and Hip Function after Prosthetic Joint Infection of the Hip? A 10-year Follow-up from Sweden

Peter Wildeman, Ola Rolfson, Bo Söderquist, Per Wretenberg, Viktor Lindgren, Peter Wildeman, Ola Rolfson, Bo Söderquist, Per Wretenberg, Viktor Lindgren

Abstract

Background: Prosthetic joint infection (PJI) is a complication after arthroplasty that negatively affects patient health. However, prior reports have not addressed the long-term consequences of hip PJI in terms of patient mortality, quality of life, and hip function.

Questions/purposes: At a minimum of 10 years after PJI in patients undergoing primary THA, in the context of several large, national databases in Sweden, we asked: (1) Is mortality increased for patients with PJI after THA compared with patients with a noninfected THA? (2) Does PJI of the hip have a negative influence on quality of life as measured by the Euro-QoL-5D-5L (EQ-5D-5L), ambulatory aids, residential status, and hip function as measured by the Oxford Hip Score (OHS)? (3) Which factors are associated with poor patient-reported outcome measures (PROMs) for patients with PJI after primary THA?

Methods: This study included 442 patients with a PJI after primary THA, from a previously published national study, including all patients with a THA performed from 2005 to 2008 in Sweden (n = 45,570) recruited from the Swedish Hip Arthroplasty Registry (SHAR). Possible deep PJIs were identified in the Swedish Dispensed Drug Registry and verified by review of medical records. Mortality in patients with PJI was compared with the remaining cohort of 45,128 patients undergoing primary THA who did not have PJI. Mortality data were retrieved from the SHAR, which in turn is updated daily from the population registry. A subgroup analysis of patients who underwent primary THA in 2008 was performed to adjust for the effect of comorbidities on mortality, as American Society of Anesthesiologists (ASA) scores became available in the SHAR at that time. For the PROM analysis, we identified three controls matched by age, gender, indication for surgery, and year of operation to each living PJI patient. A questionnaire including EQ-5D-5L, ambulatory aids, residential status, and OHS was collected from patients with PJI and controls at a mean of 11 years from the primary procedure. Apart from age and gender, we analyzed reoperation data (such as number of reoperations and surgical approach) and final prosthesis in situ to explore possible factors associated with poor PROM results.

Results: After controlling for differences in sex, age, and indication for surgery, we found the all-cause 10-year mortality higher for patients with PJI (45%) compared with patients undergoing THA without PJI (29%) (odds ratio 1.4 [95% CI 1.2 to 1.6]; p < 0.001). The questionnaire, with a minimum of 10 years of follow-up, revealed a lower EQ-5D-5L index score (0.83 versus 0.94, -0.13 [95% CI -0.18 to -0.08; p < 0.001]), greater proportion of assisted living (21% versus 12%, OR 2.0 [95% CI 1.2 to 3.3]; p = 0.01), greater need of ambulatory aids (65% versus 42%, OR 3.1 [95% 2.1 to 4.8]; p < 0.001), and a lower OHS score (36 versus 44, -5.9 [-7.7 to -4.0]; p < 0.001) for patients with PJI than for matched controls. Factors associated with lower OHS score for patients with PJI were three or more reoperations (-8.0 [95% CI -13.0 to -3.2]; p = 0.01) and a direct lateral approach used at revision surgery compared with a posterior approach (-4.3 [95% CI -7.7 to -0.9]; p = 0.01).

Conclusion: In this study, we found that PJI after THA has a negative impact on mortality, long-term health-related quality of life, and hip function. Furthermore, the subgroup analysis showed that modifiable factors such as the number of reoperations and surgical approach are associated with poorer hip function. This emphasizes the importance of prompt, proper initial treatment to reduce repeated surgery to minimize the negative long-term effects of hip PJI.

Level of evidence: Level III, therapeutic study.

Conflict of interest statement

Each author certifies that there are no funding or commercial associations (consultancies, stock ownership, equity interest, patent/licensing arrangements, etc.) that might pose a conflict of interest in connection with the submitted article related to the author or any immediate family members. All ICMJE Conflict of Interest Forms for authors and Clinical Orthopaedics and Related Research® editors and board members are on file with the publication and can be viewed on request.

Copyright © 2021 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the Association of Bone and Joint Surgeons.

Figures

Fig. 1
Fig. 1
This study flowchart shows patients with prosthetic joint infection and patients with hip arthroplasty and no history of infection in the Swedish Hip Arthroplasty Register who underwent primary THA between July 1, 2005 and December 31, 2008 and were included in this study. *Among patients with PJI, 59 did not return the questionnaire, four had dementia, and four declined to participate in the study. Among matched controls, 124 patients did not return the questionnaire, 15 had dementia, and eight declined to participate in the study.
Fig. 2
Fig. 2
This Kaplan-Meier survival curve has 95% CIs. All-cause mortality is shown for patients with prosthetic joint infection (PJI) who underwent THA and patients who underwent THA and had no history of infection. Data were extracted from the Swedish Hip Arthroplasty Register. All patients underwent THA in Sweden between July 1, 2005 and December 31, 2008.
Fig. 3.
Fig. 3.
The distribution of the OHS for patients with PJI and propensity score–matched controls is shown in this density plot. The range of the OHS is 0 to 48. Density is shown as the percentage of patients in the PJI and control groups.

References

    1. Aboltins CA, Berdal JE, Casas F, et al. Hip and knee section, prevention, antimicrobials (systemic): proceedings of international consensus on orthopedic infections. J Arthroplasty. 2019;34:S279-S288.
    1. Acree LS, Longfors J, Fjeldstad AS, et al. Physical activity is related to quality of life in older adults. Health Qual Life Outcomes. 2006;4:37.
    1. Akindolire J, Morcos MW, Marsh JD, et al. The economic impact of periprosthetic infection in total hip arthroplasty. Can J Surg. 2020;63:E52-e56.
    1. Alamanda VK, Springer BD. Perioperative and modifiable risk factors for periprosthetic joint infections (PJI) and recommended guidelines. Curr Rev Musculoskelet Med. 2018;11:325-331.
    1. Beard DJ, Harris K, Dawson J, et al. Meaningful changes for the Oxford hip and knee scores after joint replacement surgery. J Clin Epidemiol. 2015;68:73-79.
    1. Bengtsson A, Donahue GS, Nemes S, Garellick G, Rolfson O. Consistency in patient-reported outcomes after total hip replacement. Acta Orthop. 2017;88:484-489.
    1. Brown DR, Carlson SA, Kumar GS, Fulton JE. Research highlights from the status report for Step It Up! The surgeon general's call to action to promote walking and walkable communities. J Sport Health Sci. 2018;7:5-6.
    1. Bülow E, Rolfson O, Cnudde P, et al. Comorbidity does not predict long-term mortality after total hip arthroplasty. Acta Orthop. 2017;88:472-477.
    1. Cnudde P, Rolfson O, Timperley AJ, et al. Do patients live longer after THA and is the relative survival diagnosis-specific? Clin Orthop Relat Res. 2018;476:1166-1175.
    1. Dawson J, Fitzpatrick R, Carr A, Murray D. Questionnaire on the perceptions of patients about total hip replacement. J Bone Joint Surg Br. 1996;78:185-190.
    1. Downing ND, Clark DI, Hutchinson JW, Colclough K, Howard PW. Hip abductor strength following total hip arthroplasty: a prospective comparison of the posterior and lateral approach in 100 patients. Acta Orthop Scand. 2001;72:215-220.
    1. Engesaeter LB, Lie SA, Espehaug B, et al. Antibiotic prophylaxis in total hip arthroplasty: effects of antibiotic prophylaxis systemically and in bone cement on the revision rate of 22,170 primary hip replacements followed 0-14 years in the Norwegian arthroplasty register. Acta Orthop Scand. 2003;74:644-651.
    1. EuroQol. EQ-5D-5L about. 2021. EuroQol. Available at: . Accessed March 2, 2021.
    1. Friedman EM, Rodakowski J, Schulz R, et al. Do family caregivers offset healthcare costs for older adults? A mapping review on the costs of care for older adults with versus without caregivers. Gerontologist. 2019;59:e535-e551.
    1. Galea VP, Rojanasopondist P, Ingelsrud LH, et al. Longitudinal changes in patient-reported outcome measures following total hip arthroplasty and predictors of deterioration during follow-up: a seven-year prospective international multicentre study. Bone Joint J. 2019;101-b:768-778.
    1. Grammatopoulos G, Kendrick B, McNally M, et al. Outcome following debridement, antibiotics, and implant retention in hip periprosthetic joint infection- an 18 year experience. J Arthroplasty. 2017;32:2248-2255.
    1. Gundtoft PH, Pedersen AB, Varnum C, Overgaard S. Increased mortality after prosthetic joint infection in primary THA. Clin Orthop Relat Res. 2017;475:2623-2631.
    1. Henry EB, Barry LE, Hobbins AP, McClure NS, O'Neill C. Estimation of an instrument-defined minimally important difference in EQ-5D-5L index scores based on scoring algorithms derived using the EQ-VT Version 2 valuation protocols. Value Health. 2020;23:936-944.
    1. Herdman M, Gudex C, Lloyd A, et al. Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L). Qual Life Res. 2011;20:1727-1736.
    1. Hooper GJ, Rothwell AG, Frampton C, Wyatt MC. Does the use of laminar flow and space suits reduce early deep infection after total hip and knee replacement?: the ten-year results of the New Zealand Joint Registry. J Bone Joint Surg Br. 2011;93:85-90.
    1. Knight SR, Aujla R, Biswas SP. Total hip arthroplasty - over 100 years of operative history. Orthop Rev (Pavia). 2011;3:e16.
    1. Koyonos L, Zmistowski B, Della Valle CJ, Parvizi J. Infection control rate of irrigation and débridement for periprosthetic joint infection. Clin Orthop Relat Res. 2011;469:3043-3048.
    1. Kristensen TB, Vinje T, Havelin LI, Engesaeter LB, Gjertsen JE. Posterior approach compared to direct lateral approach resulted in better patient-reported outcome after hemiarthroplasty for femoral neck fracture. Acta Orthop. 2017;88:29-34.
    1. Kurtz SM, Ong KL, Lau E, Bozic KJ. Impact of the economic downturn on total joint replacement demand in the United States: updated projections to 2021. J Bone Joint Surg Am. 2014;96:624-630.
    1. Learmonth ID, Young C, Rorabeck C. The operation of the century: total hip replacement. Lancet. 2007;370:1508-1519.
    1. Lindgren JV, Wretenberg P, Karrholm J, Garellick G, Rolfson O. Patient-reported outcome is influenced by surgical approach in total hip replacement: a study of the Swedish Hip Arthroplasty Register including 42,233 patients. Bone Joint J. 2014;96-b:590-596.
    1. Lindgren V, Gordon M, Wretenberg P, Karrholm J, Garellick G. Deep infection after total hip replacement: a method for national incidence surveillance. Infect Control Hosp Epidemiol. 2014;35:1491-1496.
    1. Ludwig K, Graf von der Schulenburg JM, Greiner W. German value set for the EQ-5D-5L. Pharmacoeconomics. 2018;36:663-674.
    1. Ludvigsson JF, Almqvist C, Bonamy AK, et al. Registers of the Swedish total population and their use in medical research. Eur J Epidemiol. 2016;31:125-136.
    1. Ludvigsson JF, Otterblad-Olausson P, Pettersson BU, Ekbom A. The Swedish personal identity number: possibilities and pitfalls in healthcare and medical research. Eur J Epidemiol. 2009;24:659-667.
    1. Moss-Morris R. Adjusting to chronic illness: time for a unified theory. Br J Health Psychol. 2013;18:681-686.
    1. Murray CJ, Lopez AD. Measuring the global burden of disease. N Engl J Med. 2013;369:448-457.
    1. Murray DW, Fitzpatrick R, Rogers K, et al. The use of the Oxford hip and knee scores. J Bone Joint Surg Br. 2007;89:1010-1014.
    1. National Cancer Insitute. All cancer sites combined, SEER survival rates by time since diagnosis, 2000-2016. 2021. National Cancer Insitute. Available at: . Accessed April 13, 2021.
    1. Natsuhara KM, Shelton TJ, Meehan JP, Lum ZC. Mortality during total hip periprosthetic joint infection. J Arthroplasty. 2019;34:S337-s342.
    1. Palan J, Beard DJ, Murray DW, Andrew JG, Nolan J. Which approach for total hip arthroplasty: anterolateral or posterior? Clin Orthop Relat Res. 2009;467:473-477.
    1. Parvizi J, Zmistowski B, Berbari EF, et al. New definition for periprosthetic joint infection: from the workgroup of the Musculoskeletal Infection Society. Clin Orthop Relat Res. 2011;469:2992-2994.
    1. Petis S, Howard JL, Lanting BL, Vasarhelyi EM. Surgical approach in primary total hip arthroplasty: anatomy, technique and clinical outcomes. Can J Surg. 2015;58:128-139.
    1. Pollmann CT, Gjertsen JE, Dale H, et al. Operative approach influences functional outcome after DAIR for infected total hip arthroplasty. Bone Joint J. 2020;102-b:1662-1669.
    1. Postler AE, Beyer F, Wegner T, et al. Patient-reported outcomes after revision surgery compared to primary total hip arthroplasty. Hip Int. 2017;27:180-186.
    1. Poulsen NR, Mechlenburg I, Soballe K, Lange J. Patient-reported quality of life and hip function after 2-stage revision of chronic periprosthetic hip joint infection: a cross-sectional study. Hip Int. 2018;28:407-414.
    1. Puhto T, Puhto AP, Vielma M, Syrjala H. Infection triples the cost of a primary joint arthroplasty. Infect Dis (Lond). 2019;51:348-355.
    1. Ramocha LM, Louw QA, Tshabalala MD. Quality of life and physical activity among older adults living in institutions compared to the community. S Afr J Physiother. 2017;73:342.
    1. Robinson AH, Palmer CR, Villar RN. Is revision as good as primary hip replacement? A comparison of quality of life. J Bone Joint Surg Br. 1999;81:42-45.
    1. Saleh KJ, Celebrezze M, Kassim R, et al. Functional outcome after revision hip arthroplasty: a metaanalysis. Clin Orthop Relat Res. 2003:254-264.
    1. Steinberg JP, Braun BI, Hellinger WC, et al. Timing of antimicrobial prophylaxis and the risk of surgical site infections: results from the Trial to Reduce Antimicrobial Prophylaxis Errors. Ann Surg. 2009;250:10-16.
    1. Swedish Hip Artroplasy Registry (SHAR). 2018. Available at: . Accessed June 1,2020.
    1. Tande AJ, Patel R. Prosthetic joint infection. Clin Microbiol Rev. 2014;27:302-345.
    1. Tornero E, Morata L, Martinez-Pastor JC, et al. KLIC-score for predicting early failure in prosthetic joint infections treated with debridement, implant retention and antibiotics. Clin Microbiol Infect. 2015;21:786.e789-786.e717.
    1. Wildeman P, Tevell S, Eriksson C, et al. Genomic characterization and outcome of prosthetic joint infections caused by Staphylococcus aureus. Sci Rep. 2020;10:5938.
    1. World Health Organization. Global health risks-mortality and burden of disease attributable to selected major risks. 2009. WHO. Available at: . Accessed September 1, 2020.
    1. Wouthuyzen-Bakker M, Sebillotte M, Lomas J, et al. Clinical outcome and risk factors for failure in late acute prosthetic joint infections treated with debridement and implant retention. J Infect. 2019;78:40-47.

Source: PubMed

3
Subscribe